Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • alittleboy
    Member
    • Apr 2011
    • 60

    #1

    DEXSeq for multi-factor design

    I am using DEXSeq for testing differential exon usage between two conditions: control and treatment. For each condition, I have 8 biological replicates (C1-C8, and T1-T8). The design is listed below.

    condition subject
    C1 control 1
    C2 control 2
    C3 control 3
    C4 control 4
    C5 control 5
    C6 control 6
    C7 control 7
    C8 control 8
    T1 treatment 1
    T2 treatment 2
    T3 treatment 3
    T4 treatment 4
    T5 treatment 5
    T6 treatment 6
    T7 treatment 7
    T8 treatment 8


    As you can see from the last column, we have 8 subjects involved in the experiment. Subject 1 has both the control and the treatment, and so on for all the other subjects. This is different from the situation discussed in the DEXSeq vignette here, for example:

    design(pasillaExons)

    gives:

    condition type
    treated1fb treated single-read
    treated2fb treated paired-end
    treated3fb treated paired-end
    untreated1fb untreated single-read
    untreated2fb untreated single-read
    untreated3fb untreated paired-end
    untreated4fb untreated paired-end


    I think in the pasilla example, the biological replicates are all different. Thus in my situation, in order to see if there is differential exon usage between the treatment and control, can I do:

    (1) ignore the fact that each subject had both control and treatment? In this case, in my implementation, shall I write:

    f_dispersion = count ~ sample + condition * exon
    pExons = estimateDispersions(pExons, formula=f_dispersion)
    pExons = fitDispersionFunction(pExons)
    Null model: f_0 = count ~ sample + condition
    Alternative model: f_1 = count ~ sample + condition * I(exon == exonID)
    pExons = testForDEU(pExons, formula0 = f_0, formula1 = f_1)


    (2) incorporate the subject as a corvariate (coded that column as a factor), and then analyze in the GLM framework? In this case, in my implementation, shall I write:

    f_dispersion = count ~ sample + (condition + subject) * exon
    Null model: f_0 = count ~ sample + subject * exon + condition
    Alternative model: f_1 = count ~ sample + subject * exon + condition * I(exon == exonID)


    (3) I am not sure if including subject as a corvariate is the best approach in my situation. Are there any other options that I can consider?

    (4) I write the formula for null and alternative models exactly according to the vignette, but I am not sure if they are what I should put in R implementation.

    Thank you so much ;-)
    Last edited by alittleboy; 06-26-2013, 05:16 PM.
  • dpryan
    Devon Ryan
    • Jul 2011
    • 3478

    #2
    You'll want option (2). This happened to be recently discussed on the bioconductor email list, so have a look at that thread.

    Comment

    • alittleboy
      Member
      • Apr 2011
      • 60

      #3
      Originally posted by dpryan View Post
      You'll want option (2). This happened to be recently discussed on the bioconductor email list, so have a look at that thread.
      Hi @dpryan:

      That's a really relevant post, and it's convenient to include the subject effect in the GLM setting ;-)

      Can I know if, according to my design matrix above, the following formula are correct?

      f_dispersion = count ~ sample + (condition + subject) * exon
      Null model: f_0 = count ~ sample + subject * exon + condition
      Alternative model: f_1 = count ~ sample + subject * exon + condition * I(exon == exonID)

      Thanks!

      Comment

      • dpryan
        Devon Ryan
        • Jul 2011
        • 3478

        #4
        By my understanding, yes. Hopefully someone else will jump in if my understanding is wrong!

        Comment

        • alittleboy
          Member
          • Apr 2011
          • 60

          #5
          Originally posted by dpryan View Post
          By my understanding, yes. Hopefully someone else will jump in if my understanding is wrong!
          Hi @dpryan:

          According to this post (pretty recent!): the formula I wrote should be correct for the dispersion and testDEU ;-)

          Thanks!

          Comment

          • dpryan
            Devon Ryan
            • Jul 2011
            • 3478

            #6
            Confirmation is always good

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM
            • SEQadmin2
              Cancer Drug Resistance: The Lingering Barrier to Rising Survival
              by SEQadmin2



              Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

              There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
              07-08-2026, 05:17 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            10 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            11 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-20-2026, 11:10 AM
            0 responses
            23 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-13-2026, 10:26 AM
            0 responses
            37 views
            0 reactions
            Last Post SEQadmin2  
            Working...